Sichenzia Ross Ference Carmel LLP Represents Vyome Therapeutics in a Merger Agreement with ReShape Lifesciences

New York, NY – July 11, 2024 – Sichenzia Ross Ference Carmel LLP announced today that it represented Vyome Therapeutics, Inc., a private clinical-stage healthcare company targeting immuno-inflammatory and rare diseases, in connection with the execution of a definitive merger agreement with ReShape Lifesciences Inc, the premier physician-led weight loss and metabolic health-solutions company.  Vyome and ReShape will combine in an all-stock transaction, and be listed on Nasdaq under the new ticker symbol “HIND.”

The SRFC team was led by partners Gregory Sichenzia, Marcelle Balcombe and Glenn Burlingame and associate, Nishkarsh Jakhar.